Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
The vast majority of ketamine research has focused on intravenous infusions delivered in clinical settings. But for many patients, particularly those using at-home ketamine therapy, the route of administration is sublingual or oral. This raises a practical question: does ketamine taken by mouth or dissolved under the tongue produce meaningful antidepressant effects? While the evidence base is smaller than for IV ketamine, a growing body of real-world data suggests it may.
One study that examined oral ketamine was conducted by Jafarinia and colleagues, published in the Journal of Affective Disorders in 2016. This trial compared oral ketamine (50 mg every 3 days for 6 weeks) to diclofenac in patients with chronic pain and comorbid mild to moderate depression. While this was a specific clinical population, the ketamine group showed significant improvement in depressive symptoms compared to the diclofenac group, suggesting that even oral administration at relatively modest doses may have antidepressant properties.
Beyond this trial, several retrospective and observational studies have examined sublingual ketamine — the formulation most commonly used in at-home therapy programs. Sublingual administration involves dissolving a lozenge or troche under the tongue, where the drug is absorbed through the oral mucosa. Bioavailability via the sublingual route is estimated at roughly 25% to 30%, compared to nearly 100% for IV administration. This means that while plasma levels are lower, the drug still reaches the brain and engages the same NMDA receptor mechanism that underlies ketamine's rapid antidepressant effects.
Real-world outcome data from clinical practices offering sublingual ketamine have generally reported meaningful reductions in depression and anxiety scores, though the magnitude of effect may be somewhat more modest and gradual compared to IV protocols. The trade-off is accessibility: sublingual ketamine can be prescribed via telemedicine and administered at home under physician guidance, eliminating the need for infusion clinic visits that can cost hundreds of dollars per session and require significant time and travel.
From a physician's perspective, the route of administration question is largely pragmatic. IV ketamine achieves higher peak plasma concentrations and has the most robust clinical trial data. But IV infusions are expensive, time-intensive, and geographically inaccessible for many patients. Sublingual ketamine fills a critical gap — it enables physician-supervised treatment for patients who might otherwise have no access to ketamine therapy at all.
The clinical logic is straightforward: a treatment that produces moderate benefit and can actually be accessed by the patient is often more valuable in practice than a treatment with larger effect sizes that the patient cannot reach. Many physicians prescribing sublingual ketamine report that patients experience meaningful symptom improvement, particularly when treatment is combined with psychotherapy and ongoing clinical monitoring.
It is important to note that oral and sublingual ketamine for depression are prescribed off-label. There is no FDA approval for any form of racemic ketamine for mood disorders. Medical supervision, proper screening, and follow-up are essential.
If you're exploring ketamine therapy and wondering whether the at-home sublingual format is "enough," the available evidence suggests it may be effective for many patients. The bioavailability is lower than IV, which means the experience may be less intense and the onset of benefit may be more gradual. But for patients with treatment-resistant depression who cannot access or afford infusion clinics, sublingual ketamine represents a practical and evidence-informed option.
At-home protocols typically involve a series of sessions over several weeks, with physician check-ins and dose adjustments as needed. Many patients find that the convenience and consistency of home-based treatment supports better adherence than periodic clinic visits.
While IV ketamine has the strongest clinical trial evidence, sublingual and oral ketamine formulations appear to produce meaningful antidepressant effects in real-world practice. For patients who cannot access infusion clinics, at-home sublingual ketamine under physician supervision may offer a practical path to relief.
Reference: Jafarinia M, Afarideh M, Tafakhori A, et al. "Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: a double-blind, randomized, controlled trial." Journal of Affective Disorders. 2016;204:1-8.
If you're considering ketamine therapy, Isha Health offers physician-led at-home treatment via telemedicine in California, New York, Texas, Florida, Colorado, Arizona, Georgia, Oregon, and Washington. No in-person visit required.
